Roche's Flatiron Health, Foundation Medicine, Genentech Launch Clinico-Genomic Lung Cancer Study

May 18, 2020

|

NEW YORK – Roche companies Flatiron Health, Foundation Medicine, and Genentech announced on Monday the launch of their Prospective Clinico-Genomic (PGC) study, a collaborative effort meant to streamline clinical trials in advanced lung cancer and to identify genomic features to predict treatment response or resistance.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Roche's Flatiron Health, Foundation Medicine, Genentech Launch Clinico-Genomic Lung Cancer Study

To read the full story....

Breaking News

Invivoscribe Receives Supplemental Approval for AML Kit

Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

Genentech's Tecentriq Receives First-Line FDA Approval for High PD-L1-Expressing Lung Cancer

AstraZeneca, Daiichi Sankyo's Enhertu Gets FDA Breakthrough Status in HER2-Mutated Lung Cancer

Roche's Flatiron Health, Foundation Medicine, Genentech Launch Clinico-Genomic Lung Cancer Study

Agilent PD-L1 Assay Gets FDA Approval as Metastatic NSCLC Companion Diagnostic

Featured White Papers

Identifying Molecular Drivers of Cancer via Comprehensive Sequencing of a Large Cohort with Matched Germline and Clinical Data

What's Popular?

Opdivo, Yervoy Another First-Line Option in NSCLC, Though Maybe Not Some Oncologists' Top Choice

Janssen Antibody Produces Durable Responses in Lung Cancer Subset With Poor Prognosis

Roche's Flatiron Health, Foundation Medicine, Genentech Launch Clinico-Genomic Lung Cancer Study

Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing

FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

Sponsorships